These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 15839922)

  • 1. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R; Seftel A; Roehrborn CG
    Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
    Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
    BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alfuzosin and tamsulosin on sperm parameters in healthy men: results of a short-term, randomized, double-blind, placebo-controlled, crossover study.
    Hellstrom WJ; Sikka SC
    J Androl; 2009; 30(4):469-74. PubMed ID: 19201696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.